1. Academic Validation
  2. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication

Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication

  • J Med Chem. 2011 Jun 23;54(12):4119-32. doi: 10.1021/jm200153p.
Andrew V Stachulski 1 Chandrakala Pidathala Eleanor C Row Raman Sharma Neil G Berry Mazhar Iqbal Joanne Bentley Sarah A Allman Geoffrey Edwards Alison Helm Jennifer Hellier Brent E Korba J Edward Semple Jean-Francois Rossignol
Affiliations

Affiliation

  • 1 Robert Robinson Laboratories, Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, UK. andrew.stachulski@bioch.ox.ac.uk
Abstract

We report the syntheses and activities of a wide range of thiazolides [viz., 2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis B virus replication, with QSAR analysis of our results. The prototypical thiazolide, nitazoxanide [2-hydroxybenzoyl-N-(5-nitrothiazol-2-yl)amide, NTZ] 1 is a broad spectrum antiinfective agent effective against anaerobic bacteria, viruses, and parasites. By contrast, 2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide 3 is a novel, potent, and selective inhibitor of hepatitis B replication (EC(50) = 0.33 μm) but is inactive against anaerobes. Several 4'- and 5'-substituted thiazolides show good activity against HBV; by contrast, some related salicyloylanilides show a narrower spectrum of activity. The ADME properties of 3 are similar to 1; viz., the O-acetate is an effective prodrug, and the O-aryl glucuronide is a major metabolite. The QSAR study shows a good correlation of observed EC(90) for intracellular virions with thiazolide structural parameters. Finally we discuss the mechanism of action of thiazolides in relation to the present results.

Figures